Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast

Clinical Cancer Research

Volumn 4, Issue 4, 1998, Pages 847-854

  Alle, Kathryn M ^a   Henshall, Susan M ^a   Field, Andrew S ^a   Sutherland, Robert L ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1;

ARTICLE; BREAST CARCINOMA; BREAST EPITHELIUM; CARCINOGENESIS; CARCINOMA IN SITU; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CYCLIN D1; FEMALE; HUMANS; HYPERPLASIA; NEOPLASM PROTEINS; TUMOR CELLS, CULTURED;

EID: 0031945501     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Dupont, W. D., and Page, D. L. Risk factors for breast cancer in women with proliferative breast disease. N. Engl. J. Med., 312: 146-151, 1985.
2. O'Connell, P., Pekkel, V., Fuqua, S., Osborne, C. K., and Allred, D. C. Molecular genetic studies of early breast cancer evolution. Breast Cancer Res. Treat., 32: 5-12, 1994.
3. Man, S., Ellis, I. O., Sibbering, M., Blarney, R. W., and Brook, J. D. High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancers. Cancer Res., 56: 5484-5489, 1996.
4. Jujii, H., Marsh, C., Cairns, P., Sidransky, D., and Gabrielson, E. Genetic divergence in the clonal evolution of breast cancer. Cancer Res., 56: 1493-1497, 1996.
5. Radford, D. M., Fair, K. L., Phillips, N. J., Ritter, J. H., Steinbrueck, T., Holt, M. S., and Donis-Keller, H. Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. Cancer Res., 55: 3399-3405, 1995.
6. Murphy, D. S., Hoare, S. F., Going, J. J., Mallon, E. E. A., George, W. D., Kaye, S. B., Brown, T., Black, D. M., and Keith, W. N. Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis. J. Natl. Cancer Inst., 87: 1694-1703, 1995.
7. James, L. A., Mitchell, E. L. D., Menasce, L., and Varley, J. M. Comparative genomic hybridisation of ductal carcinoma in situ of the breast: identification of regions of DNA amplification and deletion in common with invasive breast carcinoma. Oncogene, 14: 1059-1065, 1997.
8. Chitemerere, M., Andersen, T. I., Holm, R., Karlsen, F., Børresen, A., and Nesland, J. M. TP53 alterations in atypical hyperplasia and ductal carcinoma in situ of the breast. Breast Cancer Res. Treat., 41: 103-109, 1996.
9. Allred, D. C., O'Connell, P., Fuqua, S. A. W., and Osborne, C. K. Immunhistochemical studies of early breast cancer evolution. Breast Cancer Res. Treat., 32: 13-18, 1994.
10. Bur, M. E., Zimarowski, M. J., Schnitt, S. J., Baker, S., and Lew, R. Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer (Phila.), 69: 1174-1181, 1992.
11. Panagopoulos, I., Pandis, N., Thelin, S., Petersson, C., Mertens, F., Borg, Å., Kristoffersson, U., Mitelman, F., and Åman, P. The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14. Cancer Res., 56: 4871-4875, 1996.
12. Lizard-Nacol, S., Lidereau, R., Collin, F., Arnal, M., Hahnel, L., Roignot, P., Cuisenier, J., and Guerrin, J. Benign breast disease: absence of genetic alterations at several loci implicated in breast cancer malignancy. Cancer Res., 55: 4416-4419, 1995.
13. Sherr, C. J. D-type cyclins. Trends Biol. Sci., 20: 187-190, 1995.
14. Musgrove, E. A., Hamilton, J. A., Lee, C. S., Sweeney, K. J., Watts, C. K., and Sutherland, R. L. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol. Cell. Biol., 13: 3577-3587, 1993.
15. Musgrove, E. A., Lee, C. S., Buckley, M. F., and Sutherland, R. L. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc. Natl. Acad. Sci. USA, 91: 8022-8026, 1994.
16. Sicinski, P., Donaher, J. L., Parker, S. B., Li, T., Fazeli, A., Gardner, H., Haslam, S. Z., Bronson, R. T., Elledge, S. J., and Weinberg, R. A. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell, 82: 621-630, 1995.
17. Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., and Schmidt, E. V. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature (Lond.), 369: 669-671, 1994.
18. Lydon, J. P., DeMayo, F. J., Funk, C. R., Mani, S. K., Hughes, A. R., Montgomery, C. A., Shyamala, G., Conneely, O. M., and O'Malley, B. W. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev., 9: 2266-2278, 1995.
19. Hui, R., Cornish, A. L., McClelland, R. A., Robertson, J. F. R., Blarney, R. W., Musgrove, E. A., Nicholson, R. I., and Sutherland, R. L. Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin. Cancer Res., 2: 923-928, 1996.
20. Zukerberg, L. R., Yang, W-I., Gadd, M., Thor, A. D., Koerner, F. C., Schmidt, E. V., and Arnold, A. Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. Mod. Pathol., 8: 560-566, 1995.
21. 1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J. Biol. Chem., 272: 10882-10894, 1997.
22. Buckley, M. F., Sweeney, K. J. E., Hamilton, J. A., Sini, R. L., Manning, D. L., Nicholson, R. I., deFazio, A., Watts, C. K. W., Musgrove, E. A., and Sutherland, R. L. Expression and amplification of cyclin genes in human breast cancer. Oncogene, 8: 2127-2133, 1993.
23. Bartkova, J., Lukas, J., Mülle, R. H., Lützhøft, D., Strauss, M., and Bartek, J. Cyclin D1 protein expression and function in human breast cancer. Int. J. Cancer, 57: 353-361, 1994.
24. Gillett, C., Smith, P., Gregory, W., Richards, M., Millis, R., Peters, G., and Barnes, D. Cyclin D1 and prognosis in breast cancer. Int. J. Cancer, 69: 92-99, 1996.
25. Bartkova, J., Lukas, J., Strauss, M., and Bartek, J. Cell cycle-related variation and tissue-restricted expression of human cyclin D1 protein. J. Pathol., 172: 1-9, 1994.
26. Dutta, A., Chandra, R., Leiter, L. M., and Lester, S. Cyclins as markers of tumor proliferation: immunocytochemical studies in breast cancer. Proc. Natl. Acad. Sci. USA, 92: 5386-5390, 1995.
27. McIntosh, G. G., Anderson, J. J., Milton, I., Steward, M., Parr, A. H., Thomas, M. D., Henry, J. A., Angus, B., Lennard, T. W. J., and Horne, C. H. W. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene, 11: 885-891, 1995.
28. Zhang, S-Y., Caamano, J., Cooper, F., Guo, X., and Klein-Szanto, A. J. P. Immunohistochemistry of cyclin D1 in human breast cancer. Am. J. Clin. Pathol., 102: 695-698, 1994.
29. Weinstat-Saslow, D., Merino, M. J., Manrow, R. E., Lawrence, J. A., Bluth, R. F., Wittenbel, K. D., Simpson, J. F., Page, D. L., and Steeg, P. S. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nature Med., 1: 1257-1260, 1995.
30. Tauchi, K., Hori, S., Itoh, H., Osamura, Y., Tokuda, Y., and Tajima, T. Immunohistochemical studies on oncogene products (c-erbB-2, EGFR, c-myc) and estrogen receptor in benign and malignant breast lesions. Virchow Arch. A Pathol. Anat., 416: 65-73, 1989.
31. Mizakami, Y., Nonamura, A., Noguchi, M., Taniya, T., Koyasaki, N., Saito, Y., Hashimoto, T., Matsubara, F., and Yanaihara, N. Immunohistochemical study of oncogene product Ras p21, c-Myc and growth factor EGF in breast carcinomas. Anticancer Res., 11: 1485-1494, 1991.
32. Bujovsk'y, A., Caudle, M. R., Keenan, J. A., Wimalasena, J., Foster, J. S., and Van Mete, R. S. E. Quantitative evaluation of the cell cycle-related retinoblastoma protein and localization of Thy-1 differentiation protein and macrophages during follicular development and atresia, and in human corpora lutea. Biol. Rep., 52: 776-792, 1995.
33. Bacus, S., Flowers, J. L., Pres, S. M. F., Bacus, J. W., and McCarty, K. S. The evaluation of estrogen receptor in primary breast carcinoma by computer-assisted image analysis. Am. J. Clin. Pathol., 90: 233-239, 1988.
34. Jacobs, T. W., Prioleau, J. E., Stillman, I. E., and Schnitt, S. J. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J. Natl. Cancer Inst., 88: 1054-1059, 1996.
35. Norton, A. J., Jordan, S., and Yeomans, P. Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J. Pathol., 173: 371-379, 1994.
36. Lukas, J., Pagano, M., Staskova, Z., Draetta, G., and Bartek, J. Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene, 9: 707-718, 1994.
37. Ellis, I. O., and Elston, C. W. Tumours of the breast. In: C. . M. Fletcher (ed.), Diagnostic Histopathology of Tumors, pp. 635-689. New York: Churchill Livingstone, 1995.
38. Cohen, S. M., and Ellwein, L. B. Genetic errors, cell proliferation, and carcinogenesis. Cancer Res., 51: 6493-6505, 1991.
39. Evans, T., Rosenthal, E. T., Youngblom, J., Distel, D., and Hunt, T. Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell, 33: 389-396, 1983.
40. 1 Cyclins. Cell, 73: 1059-1065, 1993.
41. Peters, G., Fantl, V., Smith, R., Brookes, S., and Dickson, C. Chromosome 11q13 markers and D-type cyclins in breast cancer. Breast Cancer Res. Treat., 33: 125-135, 1995.
42. Bartkova, J., Lukas, J., Strauss, M., and Bartek, J. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene, 10: 775-778, 1995.
43. Watts, C. K. W., Brady, A., Sarcevic, B., deFazio, A., Musgrove, E. A., and Sutherland, R. L. Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol. Endocrinol., 9: 1804-1813, 1995.
44. Welcker, M., Lukas, J., Strauss, M., and Bartek, J. Enhanced protein stability: a novel mechanism of D-type cyclin overabundance identified in human sarcoma cells. Oncogene, 13: 419-425, 1996.
45. Rosenwald, I. B., Kaspar, R., Rousseau, D., Gehrke, L., Leboulch, P., Chen, J-J., Schmidt, E. V., Sonenberg, N., and London, I. M. Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional andpost-transcriptional levels. J. Biol. Chem., 270: 21176-21180, 1995.